Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

BERWYN, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

Prior to the transaction, the Company has entered into Warrant Exchange Agreements with two investors (the "Investors") pursuant to which the Company issued to the Investors an aggregate of 1,864,000 shares of Common Stock (collectively, the "Exchange Shares") and warrants to purchase an aggregate of 874,126 shares of Common Stock, exercisable for a period of five years, at an exercise price of $.40 per share (collectively, the "Exchange Warrants"). The Exchange Shares and Exchange Warrants were issued in exchange for warrants dated as of May 9, 2007 held by the Investors to purchase an aggregate of 874,126 shares of Common Stock of the Company (collectively, the "Original Warrants").

The Company also announced that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium OY at this time. Given the Company's recent successes with respect to its strategy to grow into the world's leading vaccine franchise, including the recently announced $8.7 million of new business contract wins and the selection by a major pharmaceutical company for participation in a swine flu vaccine program, together with the investment announced today, the Company believes it is well
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... METTLER TOLEDO recently announced that a ...timization Using At-Line Particle Characterization...n this webinar, the application of in situ particl...gn space and optimize a series of roller compactio...d roller compaction forces. , ...
(Date:11/19/2009)...ould like to be able to charge their cell phones a...often. A recent discovery made by UC San Diego eng...pacitors that could do just this. , In recent r...rabhakar Bandaru, a professor in the UCSD Departme...with graduate student Mark Hoefer, have found that...
(Date:11/19/2009)...E, Nov. 19 Omeros Corpor...inancial results for the third quarter ended Septe...r 30, 2009, Omeros reported a net loss of $3.9 mil...s of $7.4 million, or $2.54 per share, for the sam...ber 30, 2009, the Company reported a net loss of $...
(Date:11/19/2009)...,, BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall...ovator in biotechnology for diabetes therapy, and ...services to food, supplement, biotechnology and ph...the previously reported $6.3 million registered di...,870 shares of its common stock and warrants to pu...
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2Nanotube defects equal better energy and storage systems 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
...on,(Nasdaq: RGEN ) announced today that the Compa.... Herlihy, Ph.D., will present at the 2008 UBS,Glo...er 24, 2008 at 1:00,p.m. EDT at the Grand Hyatt Ho...dio-webcast of the presentation will be available ... and will be archived for 30 days,following the p...
...daq: DNDN ) today announced that Mitchell H. Gold...endreon, will present a company update at the,UBS ...on Monday, September,22, 2008 at 1:30 p.m. ET., A...cessible through the,Investor Relations section of...f you are unable to listen to the live webcast,it ...
...ositions company as it expands its ...Calif., Sept. 17 Tethys Bioscience, Inc.,announce... of West,Sacramento, Calif. The acquisition will b...sing conditions. Financial terms were not disclose...abolite profiling,technology with Tethys, proven e...
Other Biology Technology:Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 2Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 3Tethys Bioscience Announces Acquisition of Lipomics Technologies 2Tethys Bioscience Announces Acquisition of Lipomics Technologies 3
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...ing the genetic instructions inside corn, one of t... of the most complex sequences of DNA ever analyze... David Schwartz, who was one of more than 100 auth...The maize genome is a true maze full of confusing... sequencers for years," says Schwartz. , Publica...
(Date:11/19/2009)...ulti-institutional effort co-led by three Cold Spr... today in publication of a landmark series of pape...nted detail the DNA sequence of maize ( Zea mays )...h American consumers, is one of the world,s most i... crop grown in the United States, representing $47...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 1Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 2Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 3Blood Mercury Levels Rising Among U S Women 55169 1Blood Mercury Levels Rising Among U S Women 55169 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10
...k species, there seems to be super-sized confusion...at the University of New Hampshire, one thing is c...ish shark populations in the past two decades. ,... many of the three-foot-long sharks that the yello...However, fishery management plans have set quotas ...
... know that the mental clarity lost because of a fe...od night,s rest. Now, UT Southwestern Medical Cent...hanism that regulates the brain,s ability to menta...with mice, they found that a molecule called an ad... animals to attain adequate levels of slow-wave ac...
...nd security, law enforcement and other first-respo...ing encouraged to attend the 2009 Force Protection...rginia this May 19-21. , , Nearly 600 exhibits wi...t, just south of Marine Corps Base, Quantico, VA. ...demonstrations will be at ranges on the Marine Cor...
Other Biology News:UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 2UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 3UT Southwestern researchers identify molecule that helps the sleep-deprived to mentally rebound 2Demonstration Targets Terrorism 2
Goat Anti-DRAK 2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
...tain a proprietary high-performance desalting resi...salting and protein-recovery characteristics compa...s containing as low as 25 g/ml of protein can be p...nd > 95% retention of salts and other small molecu...
... antibody detects an ~185 kDa protein, correspondi...orylated at tyrosine 1248 on SDS-PAGE immunoblots....rbed against the non-phosphorylated peptide to rem...ted form of the protein. In cell lines where EGFR...
Biology Products: